CTNNB1 mutations have been shown to induce the constitutive activation of the Wnt/β-catenin signaling pathway, which is associated with a specific subclass of HCC that may exhibit distinct clinical behaviors and potentially a better prognosis compared to TP53-mutant tumors. Here, CTNNB1 is linked to hepatocellular carcinoma.